IGM Biosciences Announces Refocusing of Sanofi Collaboration
17 avr. 2024 08h30 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
10 avr. 2024 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
07 mars 2024 16h10 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01 févr. 2024 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
05 déc. 2023 16h01 HE
|
IGM Biosciences, Inc.
– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All...
IGM Biosciences Announces Third Quarter 2023 Financial Results
13 nov. 2023 16h10 HE
|
IGM Biosciences, Inc.
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM...
IGM Biosciences to Present at Two Upcoming Investor Conferences
07 nov. 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
03 oct. 2023 16h05 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 sept. 2023 07h00 HE
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...